scholarly journals Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report

2021 ◽  
Vol 37 ◽  
pp. 101660
Author(s):  
Andrea Benedetto Galosi ◽  
Alessio Papaveri ◽  
Daniele Castellani ◽  
Edoardo Agostini ◽  
Luciano Burattini ◽  
...  
Keyword(s):  
Case Report ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Cell Cancer ◽  
Lessons Learned ◽  
Metastatic Renal Cell Cancer ◽  
Level Ii

scholarly journals Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report

2018 ◽  
Vol 12 (1) ◽  
Author(s):  
Jindřich Kopecký ◽  
Ondřej Kubeček ◽  
Tomáš Geryk ◽  
Birgita Slováčková ◽  
Petr Hoffmann ◽  
...  
Keyword(s):  
Case Report ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

Case Report: Long-Lasting Response in a Patient with Metastatic Renal Cell Cancer Receiving Antitumor Cytotoxic T Lymphocytes

2013 ◽  
Vol 99 (6) ◽  
pp. e282-e284 ◽  
Author(s):  
Simona Secondino ◽  
Ilaria Turin ◽  
Enrica Montini ◽  
Camillo Porta ◽  
Rita Maccario ◽  
...  
Keyword(s):  
Case Report ◽  
T Lymphocytes ◽  
Cytotoxic T Lymphocytes ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

Metastatic Non-small Cell Lung Cancer Masquerading as Metastatic Renal Cell Cancer: A Case Report

CHEST Journal ◽  
2014 ◽  
Vol 145 (3) ◽  
pp. 317A
Author(s):  
Eric Toloza ◽  
Anna Cheng ◽  
Domenico Coppola ◽  
Yuan Shan ◽  
Carla Moodie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Cell Lung Cancer ◽  
Renal Cell Cancer ◽  
Cell Lung Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Metastatic Renal Cell Cancer

Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Skin Reaction ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Cox Models ◽  
Metastatic Renal Cell Cancer ◽  
Hand Foot Skin Reaction

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.

An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study

2020 ◽  
Author(s):  
Alessandra Mosca ◽  
Ugo De Giorgi ◽  
Giuseppe Procopio ◽  
Umberto Basso ◽  
Giacomo Cartenì ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Real World ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
First Line ◽  
Free Survival ◽  
Metastatic Renal Cell Cancer ◽  
Metastatic Rcc

Abstract Objective Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials. Methods Retrospective analysis (the PAMERIT study) of first-line pazopanib in real-world metastatic renal cell cancer patients among 39 Centers in Italy. Outcomes were progression-free survival, overall survival, objective response rate and treatment-related adverse events. Kaplan–Meier curves, log-rank test and multivariable Cox’s models were used and adjusted for age, histology, previous renal surgery, International Metastatic RCC Database Consortium score and pazopanib initial dose. Results Among 474 patients, 87.3% had clear cell metastatic renal cell cancer histology. Most of them (84.6%) had upfront renal surgery. Median progression-free survival and overall survival were 15.8 and 34.4 months, respectively, significantly correlating with International Metastatic RCC Database Consortium’s good prognosis (P < 0.001), ECOG PS 0 (P < 0.001), age (<75 years, P = 0.005), surgery (P < 0.001) and response to pazopanib (P < 0.001). After 3 months of pazopanib, overall disease control rate have been observed in 76.6% patients. Among International Metastatic RCC Database Consortium’s favorable group patients, 57/121 (47%) showed complete/partial response. No unexpected AEs emerged. Conclusions In this real-world study, metastatic renal cell cancer patients treated with first-line pazopanib reached greater progression-free survival and overall survival than in pivotal studies and had high response rates when belonging to International Metastatic RCC Database Consortium’s favorable group, without new toxicities. Pazopanib has been confirmed a valid first-line option for International Metastatic RCC Database Consortium’s good prognosis metastatic renal cell cancer patients who cannot be submitted to immunotherapy.

Metastatic Renal Cell Cancer Treated with Recombinant Alpha 2a Interferon and Vinblastine

1991 ◽  
Vol 3 (6) ◽  
pp. 387-389 ◽  
Author(s):  
B. Massidda ◽  
R. Migliari ◽  
A. Padovani ◽  
R.M. Scarpa ◽  
P. Pellegrini ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?

2011 ◽  
Vol 26 (3) ◽  
pp. 273-277 ◽  
Author(s):  
Robert O. Dillman ◽  
Neil M. Barth ◽  
Louis A. VanderMolen ◽  
Warren H. Fong ◽  
Khosrow K. Mahdavi ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
High Dose ◽  
Metastatic Renal Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document